---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211956"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:25:07.040388+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Codexis Q1 revenue doubles to $15.2M; net loss narrows to $8.7M from $20.7M

## Summary
- Revenue $15.2M (up from $7.5M YoY); product gross margin 71% vs 55%.
- Net loss $8.7M ($0.10/share) vs $20.7M ($0.25) YoY; cash $65.1M.
- Reiterated FY2026 revenue guidance $72M-$76M; cash expected to fund through end 2027.
- Received ISO 9001 certification; supported FDA-approved pharma product; now 13 licensed branded drugs.
- ECO Synthesis platform: 50g siRNA supply for pre-IND; three TIDES USA presentations upcoming.

## SEC filing metadata
- accession: 0001193125-26-211956
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000119312526211956/0001193125-26-211956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000119312526211956/d112205d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211956
- JSON: https://secwatch.observer/filing/0001193125-26-211956.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211956.txt

## Source-grounded claims
- claim_id: 902201204c97a1938c109e68d454fceabef193ae
  claim: CODEXIS, INC. reported the first quarter ended March 31, 2026 results: revenue $15.2 million, net income $8.7 million, or $0.10 per share, EPS $0.10 per share. Guidance reaffirmed.
  evidence_excerpt: First Quarter 2026 Financial Highlights • Total revenues were $15.2 million for the first quarter of 2026 compared to $7.5 million in the first quarter of 2025. The increase was primarily due to the recognition of an additional $6.3 million in revenue from the Merck Technology Transfer agreement which we executed during the fourth quarter of 2025. • Product gross margin was 71% for the first quarter of 2026 compared to 55% in the first quarter of 2025. The increase in gross margin was largely due to a shift in sales toward more profitable products, and declines in less profitable, legacy products. • Research and Development expenses for the first quarter of 2026 were $11.4 million compared to $12.9 million in the first quarter of 2025. The decrease was primarily due to lower allocable costs, partially offset by higher employee-related costs and higher use of outside services. • Selling, General & Administrative expenses for the first quarter of 2026 were $9.8 million compared to $12.4
  evidence_url: https://www.sec.gov/Archives/edgar/data/1200375/000119312526211956/0001193125-26-211956-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.